As Canada gets set to implement new regulations designed to cut prescription drug spending, the pharmaceutical industry is firing back with a survey showing industry executives believe the changes will diminish their investment in the country and reduce access to medicines, among other things.

The changes, which go into effect on July 1, will alter the framework used by the Patented Medicine Prices Review Board to set prices. The agency will no longer consider prices in the U.S. and Switzerland, which have some of the world’s highest for prescription medicines, when trying to set maximum prices that drug makers may charge in Canada.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy